Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
99.57%
-
Total 13F principal
-
$728,633,184
-
Principal change
-
+$25,041,143
-
Total reported market value
-
$728,093,254
-
Number of holders
-
64
-
Value change
-
+$9,554,283
-
Number of buys
-
29
-
Number of sells
-
22
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2025
As of 30 Jun 2025,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
64 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$728,633,184
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, Opti Capital Management, LP, Point72 Asset Management, L.P., STEELHEAD PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, BlackRock, Inc., Calamos Advisors LLC, Wellesley Asset Management, MILLENNIUM MANAGEMENT LLC, and CITADEL ADVISORS LLC.
This page lists
64
institutional bondholders reporting positions
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.